- Home
- SOPH vs TCRX Comparison
SOPH vs TCRX Comparison
Compare SOPH & TCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SOPH
- TCRX
- Stock Information
- Founded
- SOPH 2011
- TCRX 2018
- Country
- SOPH Switzerland
- TCRX United States
- Employees
- SOPH N/A
- TCRX N/A
- Industry
- SOPH Biotechnology: Biological Products (No Diagnostic Substances)
- TCRX Biotechnology: Pharmaceutical Preparations
- Sector
- SOPH Health Care
- TCRX Health Care
- Exchange
- SOPH Nasdaq
- TCRX Nasdaq
- Market Cap
- SOPH 219.8M
- TCRX 82.1M
- IPO Year
- SOPH 2021
- TCRX 2021
- Fundamental
- Price
- SOPH $3.49
- TCRX $1.90
- Analyst Decision
- SOPH Buy
- TCRX Strong Buy
- Analyst Count
- SOPH 1
- TCRX 6
- Target Price
- SOPH $7.00
- TCRX $9.50
- AVG Volume (30 Days)
- SOPH 152.3K
- TCRX 628.8K
- Earning Date
- SOPH 08-05-2025
- TCRX 08-11-2025
- Dividend Yield
- SOPH N/A
- TCRX N/A
- EPS Growth
- SOPH N/A
- TCRX N/A
- EPS
- SOPH N/A
- TCRX N/A
- Revenue
- SOPH $67,173,000.00
- TCRX $4,421,000.00
- Revenue This Year
- SOPH $16.07
- TCRX $159.20
- Revenue Next Year
- SOPH $22.94
- TCRX N/A
- P/E Ratio
- SOPH N/A
- TCRX N/A
- Revenue Growth
- SOPH 4.66
- TCRX N/A
- 52 Week Low
- SOPH $2.58
- TCRX $1.02
- 52 Week High
- SOPH $4.92
- TCRX $7.89
- Technical
- Relative Strength Index (RSI)
- SOPH 70.98
- TCRX 62.32
- Support Level
- SOPH $2.81
- TCRX $1.45
- Resistance Level
- SOPH $3.40
- TCRX $1.90
- Average True Range (ATR)
- SOPH 0.30
- TCRX 0.14
- MACD
- SOPH 0.07
- TCRX 0.04
- Stochastic Oscillator
- SOPH 98.31
- TCRX 82.00
About SOPH SOPHiA GENETICS SA
Sophia Genetics SA is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It has built a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The Company had a physical presence in three countries outside of its headquarters in Switzerland: France, the United States, and Brazil.
About TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.